Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-xr for panic disorder / Julie Akiko Gladsjo en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 2 (Abril) . - pp. 131-138 Título : Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-xr for panic disorder Tipo de documento: texto impreso Autores: Julie Akiko Gladsjo, Autor ; Mark H. Rapaport, Autor ; Rebecca McKinney, Autor Fecha de publicación: 2023 Artículo en la página: pp. 131-138 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Alprazolam, Agentes ansiolíticos, Trastornos de la memoria, Pruebas Neuropsicológicas, Trastorno de pánico. Resumen: Studies to date on the effects of benzodiazepines on neuropsychologic function have yielded conflicting data with respect to the type, severity, and duration of deficits that may be induced by these agents. As part of a placebo-controlled trial of alprazolam-XR (extended release) administered in combination with cognitive-behavioral therapy in patients with panic disorder, a battery of tests was used to measure neuropsychologic function. Link: ./index.php?lvl=notice_display&id=31116 [artículo] Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-xr for panic disorder [texto impreso] / Julie Akiko Gladsjo, Autor ; Mark H. Rapaport, Autor ; Rebecca McKinney, Autor . - 2023 . - pp. 131-138. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 2 (Abril) . - pp. 131-138 Palabras clave: Alprazolam, Agentes ansiolíticos, Trastornos de la memoria, Pruebas Neuropsicológicas, Trastorno de pánico. Resumen: Studies to date on the effects of benzodiazepines on neuropsychologic function have yielded conflicting data with respect to the type, severity, and duration of deficits that may be induced by these agents. As part of a placebo-controlled trial of alprazolam-XR (extended release) administered in combination with cognitive-behavioral therapy in patients with panic disorder, a battery of tests was used to measure neuropsychologic function. Link: ./index.php?lvl=notice_display&id=31116

---

1 (1 - 1 / 1)